VANCOUVER, BC , April 17, 2024 /CNW/ - Numinus Wellness Inc. (" Numinus " or the " Company ") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal,... Read More

Numinus sharpens its focus on streamlining operations and maximizing shareholder returns through a focus on U.S. operations and strategic adjustments in its Canadian market presence. Focusing on the Numinus Network in Canada , a resource-efficient, capital-light model that enhances support for healthcare providers, offering scalable solutions in the rapidly evolving mental health care sector. Expand its Psychedelic Assisted... Read More

Q2 Fiscal 2024 Highlights Cash position of $6.6 million as of February 29, 2024 Gross profit of $0.5 million , a 22.7% decline over Q1 2024 Revenue of $5.0 million , a 15.4% decline over Q1 2024 Enrolment in Numinus training programs doubled to over 1,400 learners, compared to over 700 in Q1 2024 Managed 15 clinical trials at Cedar Clinical Research Provided 17,661 client appointments in Numinus Wellness Clinics Subsequent... Read More

VANCOUVER, BC , April 9, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioural health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 29, 2024, after market close on Monday, April 15, 2024. Interested parties are... Read More

VANCOUVER, BC , March 20, 2024 /CNW/ - Numinus Wellness Inc. (" Numinus " or the " Company ") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that it has submitted a Clinical Trial Application to Health Canada to examine the feasibility of a group model in MDMA-assisted... Read More

Announces Date of Annual General Meeting, Appointment of Directors, and Interim Chief Financial Officer VANCOUVER, BC , March 12, 2024 /CNW/ - Numinus Wellness Inc. (" Numinus " or the " Company ") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, announces that it has amended the date of its Annual... Read More

VANCOUVER, BC , March 8, 2024 /CNW/ - Numinus Wellness Inc. ( " Numinus " or the " Company ") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, congratulates Mind Medicine ("MindMed" NASDAQ: MNMD, Cboe Canada: MMED) on the positive data generated from its Phase 2b clinical trial of MM120 (lysergide... Read More

VANCOUVER, BC , Feb. 16, 2024 /CNW/ - Numinus Wellness Inc. (" Numinus ") (TSX: NUMI), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is pleased to announce the closing of its previously announced "bought deal" public offering of 50,000,000 units (each, a " Unit ") at a price of $0.12 per Unit (the " Offering... Read More

Numinus Welcomes Psychedelic Pioneer, Rick Doblin , Ph.D., as Strategic Adviser Updates Market on Closing of Previously Announced Bought Deal VANCOUVER, BC , Feb. 14, 2024 /CNW/ - Numinus Wellness Inc. (" Numinus " or the " Company ") (TSX: NUMI), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, congratulates... Read More

VANCOUVER, British Columbia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that it has entered into an agreement (the “Engagement Agreement”) with Eight Capital under which Eight Capital, on... Read More

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated September 25, 2023 to its short form base shelf prospectus dated June 27, 2023 . VANCOUVER, BC , Feb. 1, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on... Read More

In the news release issued 01-Feb-2024 at 7:00 ET by Numinus Wellness Inc. over CNW Group, we are advised by the company that changes were made in their press release. The complete, corrected release follows: CORRECTION: Numinus Wellness Divests of Holdings in Co-Investment Feeder Fund 3. This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated September 25, 2023... Read More

VANCOUVER, BC , Feb. 1, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces today that it has entered into an agreement to divest its holdings in Alto Neuroscience Inc. ("Alto"), a clinical-stage biopharmaceutical... Read More

Q1 Fiscal 2024 Highlights Gross profit of $2.1 million , an 18.8% increase over Q4 2023 Revenue of $5.9 million , a 3.0% decline over Q4 2023 Reduced operating expenditures of 19.9% over Q4 2023 Cash position of $4.7 million as at November 30, 2023 Achieved reduced cash burn rate of under $1.0 million per month beginning in October 2023 Over 700 learners enrolled in Numinus training programs Managed 22 clinical trials at... Read More

VANCOUVER, BC , Jan. 2, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioural health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2023, after market close on Tuesday, January 15, 2024. Interested parties are... Read More

VANCOUVER, BC , Dec. 15, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is proud to announce that its research site, Cedar Clinical Research (CCR), has been chosen as one of multiple sites for Beckley Psytech's... Read More

VANCOUVER, BC , Dec. 13, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, congratulates the Multidisciplinary Association of Psychedelics Studies ("MAPS" or "MAPS PBC") for its submission of a new drug application ("NDA") to the U.S. Food and Drug Administration... Read More

Q4 Fiscal 2023 Highlights Q4 2023 revenues grew 46.8% year-over-year to $6.1 million Q4 2023 revenues grew 1.7% from the previous quarter Gross profit of $1.8 million , increased 37.4% year-over-year Cash position of $8.6 million as at August 31, 2023 Achieved reduced cash burn rate of under $1.0 million per month in October 2023 Announced a partnership with the Multidisciplinary Association for Psychedelic Studies ("MAPS")... Read More

VANCOUVER, BC , Nov. 21, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2023, after market close on Wednesday, November 29, 2023. Interested parties are invited to participate in the... Read More

VANCOUVER, BC , Oct. 3, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is proud to introduce its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. Operating out of the... Read More

VANCOUVER, BC , Sept. 25, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), is pleased to announce that it has established an at-the-market equity offering program (the "ATM Program") that allows the Company to issue and sell up to C$10,000,000 of common shares in the capital of the Company (the "Common Shares") from time to time, at the Company's discretion and subject to regulatory... Read More

Study Results are widely regarded as the final step before MDMA-assisted therapy is reviewed by the FDA for wider patient access. Numinus continues to support greater access to these important therapies, through its growing psychedelic-assisted therapy practitioner training programs VANCOUVER, BC , Sept. 19, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care... Read More

The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience. Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses, which will improve company margins and support its path to profitability. VANCOUVER, BC... Read More

VANCOUVER, BC , Aug. 9, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Nikhil Handa , CFO, will participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023 , at 11:00 a.m. ET / 8:00 a.m. PT . The discussion will focus on... Read More

Q3 2023 revenues grew 713.3% year-over-year to $6.0 million Q3 2023 revenues grew 12.6% from previous quarter Gross profit of $2.1 million , increased 1051.6% year-over-year Staff reductions and operational realignment resulted in $0.6 million of one-time expenses during the quarter Cash position of $13.0 million as at May 31, 2023 Activities taken during Q3 2023 position the company well for the expected future approval of... Read More

VANCOUVER, BC , July 10, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest , Founder and CEO, will present live at the Small Cap Growth 50 Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on July 13, 2023.... Read More

VANCOUVER, BC , June 29, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended May 31, 2023 , after market close on Monday, July 17, 2023 . Interested parties are invited to participate in the Company's Q3 2023... Read More

VANCOUVER, BC , June 22, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has signed an agreement (the "Agreement") with HealingMaps – a source for individuals looking for accurate and honest information about psychedelic-assisted... Read More

Numinus has submitted a Clinical Trial Application (CTA) to Health Canada to enable MDMA-assisted therapy Experiential Opportunities for practitioners as part of an investigational Phase 1 clinical trial. If approved, Numinus intends to make the Experiential Opportunity available to practitioners as part of its psychedelic-assisted therapy education and training program. If the CTA is approved, MAPS will provide Numinus with... Read More

VANCOUVER, BC , June 14, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023 , following a thorough executive search. Current Chief Financial Officer, John Fong , will be... Read More

VANCOUVER, BC , June 8, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023 . Payton Nyquvest , Founder and CEO of Numinus,... Read More

VANCOUVER, BC , June 5, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder. CCR's research... Read More

VANCOUVER, BC , June 2, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest , Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023 , at 1:00 p.m. ET / 10:00 a.m. PT . The discussion... Read More

The research conducted at Cedar Clinical Research in Draper is part of the first ever phase 3 program of psilocybin therapy, and the largest of its kind VANCOUVER, BC , May 30, 2023 /CNW/ - Numinus Wellness Inc. (TSX: NUMI) is pleased to announce that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the... Read More

First Numinus Network™ partner enters into agreement Recent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result of recent US insurance payor code approval MDMA-assisted therapy expected to be approved for treatment in US in 2024 – Numinus well positioned to be a key... Read More

VANCOUVER, BC , April 17, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest , Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023 , at 11:30 a.m. ET / 8:30 a.m. PT . The discussion... Read More

VANCOUVER, BC , April 14, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all wellness clinics under the Numinus brand. "Our new website serves as... Read More

Q2 2023 revenues grew 581.1% year-over-year to $5.4 million Q2 2023 gross margin increased to 39.3% from 29.1% in Q2 2022 Gross profit of $2.1 million , increased 820.9% year-over-year Strong cash position of $19.7 million New licensing model designed to drive accelerated clinic growth with lower capital expenditures All financial results are reported in Canadian dollars unless otherwise stated. VANCOUVER, BC , April 13,... Read More

Licensing model enables Numinus to scale with limited capital investment and overhead Provides practitioners with an alternate model, allowing them to retain ownership of their practice and performance while leveraging Numinus patient protocols New partnership with Healing Commercial Real Estate Inc. provides Numinus Network licensees with turn-key locations VANCOUVER, BC , April 11, 2023 /CNW/ - Numinus Wellness Inc.... Read More

VANCOUVER, BC , March 30, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2023 , after market close on Thursday, April 13, 2023 . Interested parties are invited to participate in the Company's Q2... Read More

VANCOUVER, BC , March 27, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") training courses uniquely selected to provide practitioners with... Read More

VANCOUVER, BC , March 22, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday, April 5, 2023 . Payton Nyquvest , Founder and CEO of Numinus, will... Read More

VANCOUVER, BC , March 21, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Reid Robison , Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of... Read More

CEO and founder, Payton Nyquvest , to be featured on panel titled "Music as Medicine: Music as a Tool For Healing" alongside Dr. Reid Robison , Charlotte James and East Forest VANCOUVER, BC , March 7, 2023 /CNW/ - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will be featured on a panel at the upcoming... Read More

VANCOUVER, BC , Feb. 24, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking , Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023 , at 3:00 p.m. ET / 12:00 p.m.... Read More

The Phoenix Site is Numinus' Third Research Facility in the US VANCOUVER, BC , Feb. 17, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has expanded its clinical research capabilities into Arizona . The site, located in Phoenix where Numinus operates mental... Read More

VANCOUVER, BC , Feb. 15, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the " Meeting "), held earlier today. A total of 43,610,863 common shares representing... Read More

Clinical trial will be the first to test whole Psilocybe mushrooms for safety and efficacy in a clinical setting; study is expected to provide important data to support increased access to psilocybin-assisted therapy. Clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted... Read More

Q1 2023 revenues grew 618% year-over-year to $5.7 million Q1 2023 gross margin grew to 41.9% from 31.5% in prior quarter Gross profit of $2.4 million , an increase of $1.1 million from prior quarter Ended quarter with cash position of $26.4 million All financial results are reported in Canadian dollars unless otherwise stated. VANCOUVER, BC , Jan. 16, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company")... Read More